Rising Revenue and Strategic Pipeline Advances Propel Biotech Growth Trajectory
Source: Streetwise Reports  (11/8/24)
Vertex Pharmaceuticals Inc. (VRTX:NASDAQ) has reported a robust financial performance for the third quarter of 2024. Read the details on this announcement and some of the primary drivers behind the rise. More >

New Blood Cancer Treatment Shows Continued Response
Source: Dr. David Nierengarten  (11/7/24)
The biotech behind this cell therapy has numerous near-term catalysts related to its pipeline, noted a Wedbush report. More >

Regenerative Med Co. Granted Second Tissue License
Source: Dr. Jonathan Aschoff  (11/7/24)
With these expanded capabilities, the biotech may increase revenue generation and continue its clinical trial, noted a Roth MKM report. More >

Revolutionary AI Tools Take Center Stage in Medical Education Symposium
Source: Streetwise Reports  (11/5/24)
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has announced the release of its newly updated Medical Education Suite (MES). Read more to find out how this update is set to transform medical education and enhance training efficiency.

More >

Medical Co. Ready for a Transformative F2025
Source: Dr. Douglas Loe  (11/5/24)
The Leede Financial Inc. analyst also noted that while F2024 is a transition year for Profound Medical Corp. (PROF:NASDAQ; PRN:TSX), F2025 is expected to be transformative for U.S. TULSA-PRO adoption. rates. More >

Pharma Stock Has Significant Upside Potential, Analyst Says
Source: Dr. Joseph Pantginis  (11/4/24)
"We believe significant upside potential exists," H.C. Wainwright & Co. analysts wrote about Lexicon Pharmaceuticals Inc. (LXRX:NASDAQ) in an updated research note. More >

AI Healthcare Co. With 'Bright' Outlook Closes Placement
Source: Streetwise Reports  (10/31/24)
Healthcare artificial intelligence (AI) company Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has closed a non-brokered private placement for aggregate gross proceeds of CA$1.95 million. Find out why one analyst says the stock is a Strong Buy and worth going overweight on. More >

Biotech Shares Positive Phase I Data for Alzheimer's Treatment
Source: Dr. Douglas Loe  (10/31/24)
Leede Financial Inc.'s target price on ProMIS Neurosciences Inc. (PMN:TSX; PMN:NCM) reflects a potential return of 822%. More >

Mass. Biotech Shares Strong Q3 Results
Source: Dr. David Nierengarten  (10/29/24)
Kiniksa Pharmaceuticals Ltd. (KNSA:NASDAQ) recently reported strong Q3 2024 earnings, which led to its Outperform rating, according to a Wedbush research note. More >

Regenerative Medicine Co. May Have Solution to Delivering Cell Treatments
Source: Streetwise Reports  (10/28/24)
This Canadian life sciences firm is developing an implantable cell-containing pouch, shown in clinical trial data thus far to be safe, well-tolerated and effective. Learn why several analysts rate the company Buy. More >

Boston Biotech Announces Novartis Collaboration
Source: Dr. Robert Driscoll  (10/28/24)
Monte Rosa Therapeutics Inc. (GLUE:NASDAQ) recently unveiled a collaborative agreement with Novartis for the development of MRT-6160, its VAV1-degrader program, according to a Wedbush research note. More >

H.C. Wainwright & Co. Raises Price Target on Biotech Following Positive Regulatory Updates
Source: Andrew Fein  (10/23/24)
DBV Technologies SA (DBVT:NASDAQ) received a raised target price after it released long-awaited regulatory clarity regarding the path forward for its Viaskin Peanut patch. More >

Silver Break Out Confirmed
Source: Ron Struthers  (10/22/24)
The silver break out is confirmed, and Ron Struthers of Struthers Resource Stock Report expects a move to $50. He explains why he believes Coeur Mining Inc. (CDE:NYSE) offers good value and shares one biotech stock he believes is currently a sell. More >

NY Biopharma Shares Promising Clinical Data
Source: Dr. Ram Selvaraju  (10/18/24)
Anavex Life Sciences Corp. (AVXL:NASDAQ) recently released encouraging preliminary electroencephalography (EEG) biomarker results from Part A of the ongoing Phase 2 clinical study of ANAVEX3-71 for schizophrenia treatment, according to an H.C. Wainright & Co. research note. More >

Is This AI Healthcare Stock Worth Being Overweight On?
Source: Clive Maund  (10/9/24)
Technical Analyst Clive Maund explains why he thinks Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) is a Strong Buy and worth being overweight on. More >

H.C. Wainwright & Co. Shares Buy Rating on Biotech Co.
Source: Ed Arce  (10/9/24)
H.C. Wainwright & Co. analysts gave Unicycive Therapeutics Inc. (UNCY:NASDAQ) a Buy rating after the company announced the successful completion of the Phase 1 study for UNI-494 in healthy volunteers. More >

Mass. Biotech Receives FDA Approval
Source: Dr. Jonathan Aschoff  (10/7/24)
Biofrontera Inc. (BFRI:NASDAQ) receieved FDA's approval of the company's supplemental Biologics License Application (sBLA) to expand the use of Ameluz for treating larger surface areas of actinic keratosis (AK) on the face and scalp, according to a Roth MKM research note. More >

AI Integration Enhances Capabilities of Defense Drones for Key Military Operations
Source: Streetwise Reports  (10/4/24)
Red Cat Holdings Inc. (RCAT:NASDAQ) and Palladyne AI Corp. have announced a new partnership to integrate Palladyne AIs artificial intelligence (AI) platform, Palladyne Pilot, into Red Cats Teal drones. Read how this changes the capabilities for smaller scale drone platforms. More >

CT Biotech Ready for Clinical Milestones
Source: Jason Kolbert  (10/4/24)
Trevi Therapeutics Inc. (TRVI:NASDAQ) has made progress in its clinical trials for Haduvio, particularly in treating chronic cough in idiopathic pulmonary fibrosis (IPF) patients and refractory chronic cough (RCC), according to an EF Hutton research note. More >

Biotech Completes Last Patient Visit in Phase2b Osteosarcoma Trial
Source: Jason Kolbert  (10/3/24)
Following OS Therapies Inc.'s (OSTX:NYSEAMERICAN) announcement that the last patient enrolled in their Phase 2b trial for OST-HER2 in recurred, resected Osteosarcoma (OS) has completed their final radiographical evaluation, the company received a Buy rating and high target price from EF Hutton. More >

New Jersey Biotech Reports Positive Survival Data
Source: Dr. Joseph Pantginis  (10/2/24)
H.C. Wainwright & Co. analysts Dr. Joseph Pantginis gave PDS Biotechnology Corp. (PDSB:NASDAQ) a Buy rating and large target price. More >

California Biotech's Target Price 200% Higher Than Current
Source: Jason Kolbert  (9/30/24)
F Hutton analyst Jason Kolbert gave Anixa Biosciences Inc. (ANIX: NASDAQ) a high target price after it had announced it would be amending the protocol for its ongoing CAR-T therapy clinical trial for ovarian cancer, allowing for a second dose in certain patients. More >

Target Price Raised on Biotech Co.
Source: Robert Burns  (9/25/24)
In an updated assessment of Zymeworks Inc.'s (ZYME:NYSE; ZYME:TSX) pipeline potential and upcoming catalysts, H.C. Wainwright & Co. analysts raised their target price on the company. More >

CA Pharma Co. Reports Positive Phase 3 Data for Schizophrenia Treatment
Source: Jason Kolbert  (9/23/24)
Reviva Pharmaceuticals Holdings Inc. (RVPH: NASDAQ) recently reported positive Phase 3 data for its Schizophrenia treatment. The company also noted it intends to file an NDA in the first quarter of 2026, according to an EF Hutton Research note. More >

AI Collaboration to Streamline Healthcare Administration and Improve Patient Outcomes
Source: Streetwise Reports  (9/19/24)
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has formally entered a collaborative agreement with UK-based AI healthcare technology company SPRYT Limited. Read how this partnership aims to change the way patients interact with their healthcare providers. More >